Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Biotech/Pharmaceuticals
 

Company

GlaxoSmithKline
269/1
150/9
374
208
0.72
0.72
6.31
6.60
8.4
8.6
Pharmacia
178/2
222/3
349
332
0.51
0.67
16.64
10.10
10.4
9.6
Isis Pharmaceuticals
175/3
61/16
115
40
1.52
1.54
27.02
36.74
5.9
6.7
Merck
170/4
190/4
265
226
0.64
0.84
10.23
9.84
6.5
6.4
Pfizer
168/5
157/7
259
199
0.65
0.79
5.76
5.81
9.4
9.3
Aventis
154/6
345/1
375
733
0.41
0.47
7.34
3.85
10.2
9.8
Schering
147/7
68/15
112
78
1.31
0.87
6.10
5.52
8.2
8.7
Roche
139/8
223/2
263
282
0.53
0.79
17.60
16.12
8.6
8.5
Eli Lilly
125/9
168/6
174
205
0.72
0.82
7.51
9.43
8.5
8.7
AstraZeneca
94/10
105/12
204
170
0.46
0.62
7.11
5.52
9.4
8.5
Novartis
93/11
180/5
186
310
0.50
0.58
11.45
6.01
8.8
9.6
Abbott Laboratories
88/12
155/8
133
166
0.66
0.93
6.83
5.01
9.2
9.4
Novo Nordisk
75/13
84/13
183
132
0.41
0.64
3.92
6.79
7.8
8.2
Affymetrix
70/14
13/23
27
7
2.60
1.94
17.15
12.06
8.1
6.6
Bristol-Myers Squibb
63/15
123/11
117
160
0.54
0.77
10.38
9.25
9.8
8.6
BioNumerik Pharmaceuticals
53/16
5/24
23
5
2.32
0.99
23.70
18.23
3.0
9.3
Alliance Pharmaceutical
52/17
50/20
15
18
3.44
2.83
10.67
11.51
8.2
6.9
General Hospital
48/18
52/19
64
54
0.75
0.96
30.09
35.88
7.3
8.2
Takeda Chemical
43/19
57/17
86
97
0.50
0.59
11.47
3.23
8.2
9.1
Xoma
42/20
27/22
16
14
2.61
1.88
28.75
45.11
5.3
5.5
American Home Products
41/21
136/10
98
115
0.42
1.18
13.58
9.84
8.1
7.0
Schering-Plough
40/22
54/18
63
78
0.64
0.69
15.70
10.28
7.0
10.0
Incyte Genomics
37/23
71/14
149
77
0.25
0.92
9.42
10.29
3.9
4.9
Alza
37/23  
42/21
41
40
0.90
1.06
4.44
2.95
10.3
10.8

*average

Indexing Innovation

Technology Review has teamed with CHI Research of Haddon Heights, NJ, to produce the Patent Scorecard, an industry-by-industry ranking of corporate patent portfolios. CHI combines the number of a firm’s patents with other indicators to flesh out this deeper picture of innovation. Here are the specifics:

Technology Strength: This figure, the basis of the rankings, provides an overall assessment of a firm’s intellectual-property power. It is calculated by multiplying the number of a company’s U.S. patents by its Current Impact Index (see below).

Number of Patents: The total number of U.S. patents awarded, excluding design and other special-case inventions.

Current Impact Index: This measure showcases the broader significance of a company’s patents by examining how often its U.S. patents from the previous five years are cited as “prior art” in the current year’s batch. A value of 1.0 represents average citation frequency; so 1.4 would indicate a company’s patents were cited 40 percent more often than average, and so on.

Science Linkage: Patents sometimes cite scientific papers as prior art. This value shows the average number of science references listed in a company’s U.S. patents. A high figure indicates the company is closer to the cutting edge than its competitors.

Technology Cycle Time: An indicator of a firm’s speed in turning leading-edge technology into intellectual property, defined as the median age (in years) of the U.S. patents cited as prior art in the company’s patents.

0 comments about this story. Start the discussion »

Tagged: Business

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me